From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
Treatment (reference)
N
Line
ORR (%)
mPFS (months)
mOS (months)
ICI (monotherapy or combination therapy) [43]
15
≥1
6.7
2.0
5.3
ICI monotherapy [44]
11
1
9.1
11.0
3.1
ICI + platinum agent [44]
16
18.8
11.3
4.5
32
≥2
8.1
2.3
20
5
7.1
2.2